Bravis Ziekenhuis

At Bravis Ziekenhuis, clinical research in cardiovascular diseases focuses on major conditions such as atherosclerotic cardiovascular disease, acute coronary syndrome, acute myocardial infarction, and stroke prevention in atrial fibrillation. These studies are designed to test new ways to reduce serious heart and blood vessel events, improve protection against clot-related complications, and strengthen long-term cardiovascular care.

• Testing therapies to lower the risk of major adverse cardiovascular events after heart attack or in people at high cardiovascular risk
• Evaluating treatments for stroke and systemic embolism prevention in atrial fibrillation
• Studying options for patients with elevated lipoprotein(a) and broader ASCVD risk
• Assessing self-administered treatment approaches for suspected recurrent myocardial infarction

Overall, this research area is centered on improving prevention and treatment for high-risk cardiovascular patients while also exploring safer and more effective options for everyday clinical use.

Research in digestive system diseases at this hospital includes work on predicted severe acute pancreatitis. The main goal is to find better supportive treatments that can reduce complications, limit organ failure, and improve survival in patients facing this serious inflammatory condition.

• Investigating therapies aimed at reducing organ failure and mortality in severe acute pancreatitis
• Exploring whether early treatment can improve recovery and reduce the need for intensive care
• Assessing patient outcomes, including complications, hospital stay, and overall quality of life

This work reflects a strong interest in finding practical treatment strategies for a life-threatening digestive disease where early intervention may make a meaningful difference.

Clinical trials in male urogenital diseases at Bravis Ziekenhuis are focused on low-volume metastatic castration-sensitive prostate cancer. The research is aimed at improving treatment balance by studying whether some therapy can be safely reduced without losing effectiveness, with the broader goal of lowering side effects and treatment burden.

• Evaluating treatment strategies for prostate cancer that may preserve disease control while reducing toxicity
• Looking at ways to maintain effectiveness while limiting long-term use of androgen receptor signaling inhibitors
• Supporting more personalized care for men with metastatic castration-sensitive prostate cancer

This area of research is especially relevant for patients and clinicians seeking approaches that combine cancer control with better tolerability and lower treatment costs.

The site also contributes to broader neoplasms research, with studies that connect oncology and cardiovascular care in patients with cancer-related or treatment-related risk. This reflects the hospital’s Medical Oncology focus and its interest in improving outcomes for patients with complex, high-risk disease profiles.

• Exploring treatment approaches that support cancer care while reducing unwanted complications
• Studying how therapy choices may affect overall health and long-term disease control
• Contributing to research that links oncology with broader patient safety and quality-of-life goals

These studies aim to refine cancer treatment decisions and support more effective, patient-centered care in routine practice.